Oncology Brothers on X: "3. #EMERALD trial for #Elacestrant HR+ mESR1 advanced breast CA -median PFS was 3.8 month - Common AE: musculoskeletal pain, nausea, increased cholesterol #bcsm https://t.co/xCWNyXRObk https://t.co/Jjwpif9xeq https://t.co ...
Hagen Kennecke on X: "EMERALD-1: Addition of Durva + Bev but not Durva to TACE improves PFS in large placebo-controlled trial. Other trials of Combo Tx plus TACE awaited. https://t.co/bcVCMD6eU5" / X
Bertrand Delsuc on X: "$AZN Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial hit on PFS for durva+beva+TACE in HCC (
Report Back from SABCS 2021: What's the Latest in MBC Research? — Our MBC Life
EMERALD Trial | ORSERDU™ (elacestrant) Efficacy
EMERALD Trial | ORSERDU™ (elacestrant) Efficacy
Elacestrant vs Endocrine Monotherapy in Advanced Breast Cancer: Phase III EMERALD Trial - The ASCO Post
Katherine Sanchez MD on X: "Breast cancer has had so many big wins this year. Check out our review of elacestrant, the first trial reporting a pill formulation of SERD is effective,
Imfinzi (durvalumab) plus bevacizumab met endpoints in EMERALD-1 Phase III results in Liver Cancer - YouTube
EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer | Future Oncology
Emerald 1: A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional ...
EMERALD Pancreas — Department of Oncology
EMERALD Trial | ORSERDU® (elacestrant) Efficacy
EMERALD Trial: Elacestrant for ER+/HER2- Metastatic Breast Cancer
EMERALD Phase 3 Trial of Elacestrant Versus Standard of Care Endocrine Therapy in Patients With ER+/HER2- Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting
On trial: Emerald Insight Expert Briefings - Library Matters
SABCS 2022: EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting
ER+, HER2- Advanced Breast Cancer: Clinical Implications of the EMERALD Trial
EMERALD Study Orkin C. Lancet HIV. 2018 Jan;5(1):e23-e34.
Clinical outcomes of patients within the EMERALD trial of elacestrant... | Download Scientific Diagram
Elacestrant Impresses in EMERALD Trial of Breast Cancer
Laila Agrawal, MD on X: "Results from #EMERALD with oral #SERD elacestrant presented at #SABCS21. Improved PFS from 2.79 to 1.91 mo with greater separation at 6mo and 12mo. I had the
Resources to support your trial | Emerald Publishing
EMERALD Trial | ORSERDU™ (elacestrant) Efficacy
